CAVIN1

Chr 17AR

caveolae associated protein 1

Also known as: CAVIN, CGL4, FKSG13, PTRF, cavin-1

This gene encodes a protein that enables the dissociation of paused ternary polymerase I transcription complexes from the 3' end of pre-rRNA transcripts. This protein regulates rRNA transcription by promoting the dissociation of transcription complexes and the reinitiation of polymerase I on nascent rRNA transcripts. This protein also localizes to caveolae at the plasma membrane and is thought to play a critical role in the formation of caveolae and the stabilization of caveolins. This protein translocates from caveolae to the cytoplasm after insulin stimulation. Caveolae contain truncated forms of this protein and may be the site of phosphorylation-dependent proteolysis. This protein is also thought to modify lipid metabolism and insulin-regulated gene expression. Mutations in this gene result in a disorder characterized by generalized lipodystrophy and muscular dystrophy. [provided by RefSeq, Nov 2009]

OMIMResearchGenerating clinical summary…
MultiplemechanismARLOEUF 1.081 OMIM phenotype
Clinical SummaryCAVIN1
🧬
Gene-Disease Validity (ClinGen)
lipodystrophy · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
16 unique Pathogenic / Likely Pathogenic· 95 VUS of 184 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.08LOEUF
pLI 0.005
Z-score 1.40
OE 0.51 (0.271.08)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
1.38Z-score
OE missense 0.76 (0.670.85)
195 obs / 257.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.51 (0.271.08)
00.351.4
Missense OE?0.76 (0.670.85)
00.61.4
Synonymous OE?0.88
01.21.6
LoF obs/exp: 5 / 9.7Missense obs/exp: 195 / 257.1Syn Z: 1.08

This gene — mechanism propensity

DN
0.6065th %ile
GOF
0.78top 25%
LOF
0.4332th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
LOF100% of P/LP variants are LoF

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

184 submitted variants in ClinVar

Classification Summary

Pathogenic10
Likely Pathogenic6
VUS95
Likely Benign39
Benign21
Conflicting11
10
Pathogenic
6
Likely Pathogenic
95
VUS
39
Likely Benign
21
Benign
11
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
10
0
0
0
10
Likely Pathogenic
6
0
0
0
6
VUS
0
67
23
5
95
Likely Benign
0
2
17
20
39
Benign
0
0
20
1
21
Conflicting
11
Total16696026182

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

6 pathogenic / likely-pathogenic (of 7) ClinVar copy-number / structural variants overlap CAVIN1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

CAVIN1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →